Owkin S News Today : Breaking News, Live Updates & Top Stories | Vimarsana

And here we have the information that you receive after the ai has looked at the data? exactly. so here, for example, i can see that the ai risk is low. it's a low—risk patient. some cancer experts see real promise in al tools like owkin�*s, but there are still challenges. it's really exciting work, - and it's showing where the future lies for pathology. while it might not be absolutely. there yet for clinical deployment, i think it's a really important first step and something - that we should be encouraged by. the real benefit to patients of these is patient safety . in the first instanc...

Made its assessment of the risk. in this case, it's low, but when it's at a more moderate level, the dilemma really exists. sometimes, there is a grey zone and some cases are borderline, so maybe not completely good prognosis, maybe completely bad. and in this grey zone, we need other tools to decide for the prognosis of the patient. and here, we have the information that you receive after the al's looked at the data. exactly. so here, for example, i can see that the ai risk is low — it's a low—risk patient. some cancer experts see real promise in al tools like owkin's, but there are still...

So here, for example, i can see that the ai risk is low — it's a low—risk patient. some cancer experts see real promise in al tools like owkin's, but there are still challenges. it's really exciting - work and it's showing where the future lies for pathology. while it might not be absolutely. there yet for clinical deployment, i think it's a really important first step, and something. that we should be encouraged by. the real benefit to patients of these is patient safety . in the first instance — _ to make sure that we don't miss cancers, that we can detect small. areas of cancer that c...